Harlan Japan Names New President - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Harlan Japan Names New President



Harlan has announced Hiroharu Okochi as president of Harlan Japan.

Okochi will have full profit and loss responsibility as well as overall accountability for all aspects of the Harlan Contract Research Services business tream serving the Japanese chemical, agrochemical, and pharmaceutical markets.

Prior to joining Harlan, Okochi was responsible for sales and business development of Covance central laboratory services to Japanese pharmaceutical companies. He also held research positions at Shin Nippon Biomedical Laboratories, including the position of general manager of SNBL’s Cambodia subsidiary, where he was responsible for production control and negotiating with the Cambodian government.

Source: Harlan Japan

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here